1. Home
  2. VOR vs NEO Comparison

VOR vs NEO Comparison

Compare VOR & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vor Biopharma Inc.

VOR

Vor Biopharma Inc.

HOLD

Current Price

$20.82

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo NeoGenomics Inc.

NEO

NeoGenomics Inc.

HOLD

Current Price

$15.58

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VOR
NEO
Founded
2015
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Precision Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.2B
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
VOR
NEO
Price
$20.82
$15.58
Analyst Decision
Buy
Strong Buy
Analyst Count
10
8
Target Price
$45.33
$13.38
AVG Volume (30 Days)
1.2M
3.0M
Earning Date
05-11-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$10.63
Revenue Next Year
N/A
$9.73
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.62
$5.09
52 Week High
$49.95
$16.17

Technical Indicators

Market Signals
Indicator
VOR
NEO
Relative Strength Index (RSI) 61.60 65.38
Support Level $11.62 $11.49
Resistance Level $22.22 N/A
Average True Range (ATR) 1.44 0.76
MACD 0.11 0.00
Stochastic Oscillator 82.31 84.13

Price Performance

Historical Comparison
VOR
NEO

About VOR Vor Biopharma Inc.

Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.

About NEO NeoGenomics Inc.

NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

Share on Social Networks: